Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 376

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 376
---
 short maturities.

Non-financial assets such as property and equipment
are evaluated for impairment and adjusted to fair value using Level 3 inputs only when impairment is recognized. Fair values are
considered Level 3 when management makes significant assumptions in developing a discounted cash flow model based upon a number of
considerations including projections of revenues, earnings, and a discount rate. To date, the Company has not recorded any adjustments
to fair value related to impairment on property and equipment.

F-57 CERo Therapeutics, Inc. Notes to Financial Statements

|                                   |     | December 31, 2023 |   |     |         |   |     |         |         |     |       |         |
|:----------------------------------|:----|:------------------|:--|:----|:--------|:--|:----|:--------|--------:|:----|:------|--------:|
|                                   |     | Level 1           |   |     | Level 2 |   |     | Level 3 |         |     | Total |         |
| Preferred stock warrant liability |     | $                 | - |     | $       | - |     | $       | 320,117 |     | $     | 320,117 |

|                                   |     | December 31, 2022 |   |     |         |   |     |         |         |     |       |         |
|:----------------------------------|:----|:------------------|:--|:----|:--------|:--|:----|:--------|--------:|:----|:------|--------:|
|                                   |     | Level 1           |   |     | Level 2 |   |     | Level 3 |         |     | Total |         |
| Preferred stock warrant liability |     | $                 | - |     | $       | - |     | $       | 610,381 |     | $     | 610,381 |

| Balance at December 31, 2021             |     | $ |  647,373 |   |
| Gain on revaluation of warrant liability |     |   |  (36,992 | ) |
| Balance at December 31, 2022             |     | $ |  610,381 |   |
| Gain on revaluation of warrant liability |     |   | (290,264 | ) |
| Balance at December 31, 2023